A polycythemia vera JAK2 mutation masquerading as a duodenal cancer mutation

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 12, 2016, Pages 1495-1498

  Lee, Justin ^a   Axilbund, Jennifer ^a   Brian Dalton, W ^a   Laheru, Daniel ^a   Watkins, Stanley ^a   Chu, David ^a   Cravero, Karen ^a   Button, Berry ^a   Kyker Snowman, Kelly ^a   Waters, Ian ^a   Gocke, Christopher D ^a   Lauring, Josh ^a   Park, Ben Ho ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CELL DNA; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; JANUS KINASE 2; OXALIPLATIN; RUXOLITINIB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; JAK2 PROTEIN, HUMAN; PLATINUM COMPLEX;

ADVERSE DRUG REACTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CHEEK CELL; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM CANCER; FALSE POSITIVE RESULT; FEMALE; GENE MUTATION; HETEROZYGOSITY; HOSPICE CARE; HUMAN; HUMAN TISSUE; MEDICAL HISTORY; NEXT GENERATION SEQUENCING; PATIENT REFERRAL; POLYCYTHEMIA VERA; SOMATIC MUTATION; ABDOMINAL PAIN; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BLOOD CELL; COMPLICATION; CYTOLOGY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DNA CONTAMINATION; DNA SEQUENCE; DUODENAL NEOPLASMS; DUODENUM; GENETICS; HETEROZYGOTE; HIGH THROUGHPUT SEQUENCING; MOUTH MUCOSA; MUTATION; NAIL; PANCREATICODUODENECTOMY; PATHOLOGY; PHLEBOTOMY; PROCEDURES; X-RAY COMPUTED TOMOGRAPHY;

ABDOMINAL PAIN; ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; DIAGNOSIS, DIFFERENTIAL; DNA CONTAMINATION; DUODENAL NEOPLASMS; DUODENUM; FEMALE; FLUOROURACIL; HETEROZYGOTE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HOSPICE CARE; HUMANS; JANUS KINASE 2; LEUCOVORIN; MOUTH MUCOSA; MUTATION; NAILS; ORGANOPLATINUM COMPOUNDS; PANCREATICODUODENECTOMY; PHLEBOTOMY; POLYCYTHEMIA VERA; SEQUENCE ANALYSIS, DNA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85006056573     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0161     Document Type: Article

References (9)

1. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015;7:283ra53.
2. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
3. Etheridge SL, Cosgrove ME, Sangkhae V, et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 2014;123:1059-1068.
4. Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014;123:1372-1383.
5. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 2012;366:967-969.
6. Thiede C, Prange-Krex G, Freiberg-Richter J, et al. Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants. Bone Marrow Transplant 2000;25:575-577.
7. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010;12:425-432.
8. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012;12:849-859.
9. Preuner S, Danzer M, Proll J, et al. High-quality DNA from fingernails for genetic analysis. J Mol Diagn 2014;16:459-466.